全身抗菌预防与抗菌涂层脑室外引流管预防脑室造瘘相关感染:5242例荟萃分析
该荟萃分析检索PubMed相关文献,纳入19项研究共5242例脑室造瘘结局,评估延长全身抗菌预防和抗菌涂层脑室外引流管对脑室造瘘相关感染发生率的影响。延长静脉预防和抗菌涂层引流管的风险比分别为0.36和0.39,联合预防时预期感染率可低至0.8%至2%。
要点
- 联合延长静脉预防和抗菌涂层引流管时预期感染率为0.8%至2%。
核心结论
- 延长全身抗菌预防联合抗菌涂层脑室外引流管可能降低脑室造瘘患者的感染风险,但对相关发病率、死亡率、医疗费用和住院时间的影响仍不明确。
研究设计与样本
- 检索PubMed中与脑室造瘘相关感染和抗菌预防相关的研究,纳入报告对照组和治疗组感染发生率的合格文献,评估延长全身抗菌预防(>24小时)或抗菌涂层脑室外引流管。
- 共纳入19项研究(占604篇文献的3%),报告5242例脑室造瘘结局,采用随机或混合效应模型汇总风险比和感染发生率,使用I2和Cochran Q统计量量化异质性,并遵循PRISMA指南。
主要发现
- 混合效应分析显示无预防时预期感染率为13%至38%,围手术期静脉预防为7%至18%,延长静脉预防或抗菌涂层引流管单药预防为3%至9%,延长静脉预防联合抗菌涂层引流管双药预防低至0.8%至2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: External ventricular drain (EVD) placement is essential for the management of many neurocritical care patients. However, ventriculostomy-related infection (VRI) is a serious complication, and there remains no well-established protocol guiding use of perioperative or extended antibiotic prophylaxis to minimize risk of VRI. OBJECTIVE: To analyze published evidence on the efficacy of extended prophylactic antimicrobial therapy and antibiotic-coated external ventricular drains (ac-EVDs) in reducing VRI incidence. METHODS: We searched PubMed for studies related to VRIs and antimicrobial prophylaxis. Eligible articles reported VRI incidence in control and treatment cohorts evaluating prophylaxis with either extended systemic antibiotics (> 24 hr) or ac-EVD. Risk ratios and VRI incidence were aggregated by prophylactic strategy, and pooled estimates were determined via random or mixed effects models. Study heterogeneity was quantified using I2 and Cochran's Q statistics. Rigorous assessment of study bias was performed, and PRISMA guidelines were followed throughout. RESULTS: Across 604 articles, 19 studies (3%) met eligibility criteria, reporting 5242 ventriculostomy outcomes. Extended IV and ac-EVD prophylaxis were associated with risk ratios of 0.36 [0.14, 0.93] and 0.39 [0.21, 0.73], respectively. Mixed effects analysis yielded expected VRI incidence of 13% to 38% with no prophylaxis, 7% to 18% with perioperative IV prophylaxis, 3% to 9% with either extended IV or ac-EVD prophylaxis as monotherapies, and as low as 0.8% to 2% with extended IV and ac-EVD dual prophylaxis. CONCLUSION: Management with both extended systemic antibiotics and ac-EVDs could lower VRI risk in ventriculostomy patients, but the impact on associated morbidity and mortality, healthcare costs, and length of stay remain unclear.
引用
- Sheppard JP, Ong V, Lagman C, et al. Systemic Antimicrobial Prophylaxis and Antimicrobial-Coated External Ventricular Drain Catheters for Preventing Ventriculostomy-Related Infections: A Meta-Analysis of 5242 Cases. Neurosurgery. 2020. PMID: 30476297. doi:10.1093/neuros/nyy522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。